ATE139255T1 - Oligonukleotidanaloga mit neuartigen bindungen - Google Patents

Oligonukleotidanaloga mit neuartigen bindungen

Info

Publication number
ATE139255T1
ATE139255T1 AT90916934T AT90916934T ATE139255T1 AT E139255 T1 ATE139255 T1 AT E139255T1 AT 90916934 T AT90916934 T AT 90916934T AT 90916934 T AT90916934 T AT 90916934T AT E139255 T1 ATE139255 T1 AT E139255T1
Authority
AT
Austria
Prior art keywords
oligonucleotide compounds
bindings
novel
oligonucleotide analogues
nucleotides
Prior art date
Application number
AT90916934T
Other languages
English (en)
Inventor
Mark Matteucci
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/559,957 external-priority patent/US5264564A/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ATE139255T1 publication Critical patent/ATE139255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90916934T 1989-10-24 1990-10-24 Oligonukleotidanaloga mit neuartigen bindungen ATE139255T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42628689A 1989-10-24 1989-10-24
US44894189A 1989-12-11 1989-12-11
US07/559,957 US5264564A (en) 1989-10-24 1990-07-30 Oligonucleotide analogs with novel linkages

Publications (1)

Publication Number Publication Date
ATE139255T1 true ATE139255T1 (de) 1996-06-15

Family

ID=27411504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90916934T ATE139255T1 (de) 1989-10-24 1990-10-24 Oligonukleotidanaloga mit neuartigen bindungen

Country Status (8)

Country Link
EP (1) EP0498843B1 (de)
JP (1) JPH05504553A (de)
KR (1) KR920702409A (de)
AT (1) ATE139255T1 (de)
AU (1) AU653504B2 (de)
CA (1) CA2071483C (de)
DE (1) DE69027443T2 (de)
WO (1) WO1991006629A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5495009A (en) * 1989-10-24 1996-02-27 Gilead Sciences, Inc. Oligonucleotide analogs containing thioformacetal linkages
ES2083593T3 (es) * 1990-08-03 1996-04-16 Sterling Winthrop Inc Compuestos y metodos para inhibir la expresion de genes.
JPH06505704A (ja) * 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
US5495006A (en) * 1991-09-27 1996-02-27 Allelix Biopharmaceuticals, Inc. Antiviral polynucleotide conjugates
HU9501994D0 (en) * 1993-03-31 1995-09-28 Sterling Winthrop Inc Novel 5'-substituted nucleosides and oligomers produced therefrom
US5580972A (en) * 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US6605708B1 (en) * 1993-07-28 2003-08-12 Hybridon, Inc. Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
US5646269A (en) * 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
CA2223088A1 (en) 1995-06-07 1996-12-19 Bob Dale Brown Novel carbamate-based cationic lipids
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US5959100A (en) 1996-03-27 1999-09-28 Nexstar Pharmaceuticals, Inc. Pyrimidine nucleosides as therapeutic and diagnostic agents
US5945527A (en) * 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6007992A (en) * 1997-11-10 1999-12-28 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US6028183A (en) * 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
PT1105485E (pt) 1998-08-21 2006-11-30 Immunex Corp Dna e polipeptídeos de il-1 epsilon humana
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
EP1185639B1 (de) 1999-03-26 2010-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
EP1953173B1 (de) 1999-06-15 2009-11-18 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897943B1 (de) 1999-12-23 2011-12-14 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP1265920B9 (de) 2000-03-22 2007-01-24 Curagen Corporation Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1992643A3 (de) 2001-06-20 2008-12-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP2143438B1 (de) 2001-09-18 2011-07-13 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
EP2110434A1 (de) 2002-02-25 2009-10-21 Genentech, Inc. Typ-1 Cytokine Rezeptor GLM-R
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
AU2003243400B2 (en) 2002-06-07 2009-10-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2424353T3 (es) 2003-07-08 2013-10-01 Genentech, Inc. Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos
NZ596984A (en) 2003-11-17 2013-10-25 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
US20060281680A1 (en) 2005-03-10 2006-12-14 Genentech, Inc. Methods and compositions for modulating vascular integrity
NZ563341A (en) 2005-06-06 2009-10-30 Genentech Inc Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
CA2619577A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1940470B1 (de) 2005-09-26 2013-04-17 Medarex, Inc. Antikörper-Arzneimittel-Konjugate und deren Anwendung
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
WO2007126439A2 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
WO2008033782A2 (en) 2006-09-12 2008-03-20 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
PE20090510A1 (es) 2007-08-03 2009-05-22 Summit Corp Plc Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
NO2514436T3 (de) 2007-11-07 2018-05-19
WO2010024927A2 (en) 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
WO2010062995A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
EP2213682A1 (de) 2009-01-30 2010-08-04 Institut Curie TSLP fördert Immunevasion und Persistenz von Viren
EP2266550A1 (de) 2009-06-15 2010-12-29 Institut Curie Antagonisten von ß-Catenin zur Prävention und/oder Behandlung neurodegenerativer Erkrankungen
EP2473522B1 (de) 2009-09-02 2016-08-17 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
JP6016636B2 (ja) 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
TWI537383B (zh) 2009-11-30 2016-06-11 建南德克公司 診斷及治療腫瘤之組合物及方法
CA2787657A1 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BR112012025872B8 (pt) 2010-04-12 2021-05-25 Somalogic Inc primidinas modificadas na posição-5
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
EP2625197B1 (de) 2010-10-05 2016-06-29 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
WO2014154898A1 (en) 2013-03-29 2014-10-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Prognosis and treatment of cancers
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
EP3411396A1 (de) 2016-02-04 2018-12-12 Curis, Inc. Smoothened-mutant und verfahren zur verwendung davon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
WO1989005853A1 (en) * 1987-12-15 1989-06-29 Synthetic Genetics Nucleic acid chelate conjugate as therapeutic and diagnostic agents

Also Published As

Publication number Publication date
WO1991006629A1 (en) 1991-05-16
DE69027443T2 (de) 1998-03-19
EP0498843A4 (en) 1992-11-04
AU6724590A (en) 1991-05-31
CA2071483C (en) 2001-04-17
KR920702409A (ko) 1992-09-04
DE69027443D1 (de) 1996-07-18
AU653504B2 (en) 1994-10-06
EP0498843A1 (de) 1992-08-19
EP0498843B1 (de) 1996-06-12
JPH05504553A (ja) 1993-07-15
CA2071483A1 (en) 1991-04-25

Similar Documents

Publication Publication Date Title
ATE139255T1 (de) Oligonukleotidanaloga mit neuartigen bindungen
EP0643720A4 (en) Binding competent oligomers containing 2', 5' linkages.
CA2266748A1 (en) Three component chimeric antisense oligonucleotides
ATE521356T1 (de) Kohlehydraten oder 2'-modifizierten oligonukleotiden mit alternierenden internukleoside-bindungen
PT92640A (pt) Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules by forming a colinear triplex the synthetic oligonucleotides and methods of use
DE69838449D1 (de) Aminooxy-modifizierte oligonukleotide
ATE316094T1 (de) Oligonukleotide mit für bindungstaschen spezifischen chiralen phosphorothioat- internukleosidbindungen
DE69431164D1 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
BR9206049A (pt) Composto, processos para preparar o composto, para o reconhecimento específico por sequência de um polinucleotídio de filamento duplo, para modular a expressão de um gene em um organismo, para tratar as condições associadas com produção de proteínas indesejada em um organismo, para induzir a degradação de DNA ou RNA em células de um organismo e para exterminar células ou vírus e composição farmacêutica
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
DE69126710D1 (de) Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen
DK0549615T3 (da) Sukkermodificerede oligonukleotider der påviser og modulerer genekspression
FI925103A0 (fi) Antisense-inhibitorer av humant immunbristvirus
WO1999009154A3 (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
ATE221127T1 (de) Über chirale phosphoratome gebundene oligonukleotide
NZ331358A (en) Methoxyethoxy oligonucleotides for modulation of protein kinase c expression
WO1995003406A3 (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
WO2000008140A3 (en) Antisense oligonucleotides for the inhibition of vegf expression
WO1994013789A3 (en) Oligonucleotides with rna cleavage activity
EP1212455A4 (de) Antisense modulation der expression des telomerwiederholungsbindungsfaktor 1
RU98117073A (ru) Модифицированные сахаром, содержащие "гэпы" олигонуклеотиды
Nb et al. The genome of the pogonophoran Siboglinum fiordicum-characteristics of its organization and divergence from the genomes of several representative invertebrate animals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties